Safety and Efficacy of Fenofibrate in the Treatment of Pregnant Women With Severe Hypertriglyceridemia
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this study is to evaluate the safety of fenofibrate in severe hypertriglyceridemia pregnant women.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 20
Maximum Age: 45
Healthy Volunteers: f
View:
• 20-45 years pregnant women; TG level ≥10mM； Voluntary signed informed consent (prospective study) or voluntary consent to use of medical information (retrospective analysis)
Locations
Other Locations
China
Hangzhou First People's Hospital
RECRUITING
Hangzhou
Contact Information
Primary
Zhiyuan Ma, PhD
mazy1990@163.com
18858273870
Time Frame
Start Date: 2022-06-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 250
Treatments
fenofibrate group
Women with TG level ≥10mM receive fenofibrate micronized capsule（200mg ，qd）or table（160mg ，qd）for at least 1 week during pregnancy.
negative group
Pregnant women with TG level ≥10mM without fenofibrate treatment.
Related Therapeutic Areas
Sponsors
Leads: First People's Hospital of Hangzhou